lates microvascular permeability Am. J. Physiol. 262 (Heart Circ. Physiol. 31): H611-H615, 1992.-We recently demonstrated that inhibitors of nitric oxide (NO) production cause a dramatic increase in leukocyte adherence and emigration in postcapillary venules. The objective of this study was to assess whether inhibition of NO production leads to vascular protein leakage and increased microvascular permeability in feline small intestine and to determine whether adherent leukocytes contribute to these responses. Whereas 2VC;-nitro-L-arginine methyl ester (L-NAME) produced fivefold increases in microvascular fluid and protein fluxes, capillary pressure remained unchanged. In some experiments, venous pressure was elevated and the microvascular reflection coefficient for total proteins (Q) was estimated from lymph to plasma protein concentration ratio at high capillary filtration rates. L-NAME infusion increased 1 -ud (permeability index) from a control value of 0.21 t 0.02 to 0.41 t 0.07. All of the L-NAME-induced microvascular alterations were completely reversed by nitroprusside. Some animals were pretreated with a monoclonal antibody (MoAb IB,) directed against the leukocyte adhesion glycoprotein complex CDll/CDlS.
MoAb IB, did not prevent the initial rise in vascular protein leakage but greatly attenuated the later (30-60 min) phase of enhanced vascular protein leakage. Local intra-arterial infusion of the NO synthesis inhibitor L-NAME (0.025 pmol . ml-l. min-l) produced a profound increase in leukocyte adhesion in postcapillary venules that was partly reversed by sodium nitroprusside administration (0.025 pmol l ml-l l min).
These results suggest that inhibition of NO production by vascular endothelium leads to a reversible increase in microvascular protein efflux that is mediated by both leukocyte-dependent and -independent mechanisms. leukocyte integrins; leukocyte adhesion; N<"-nitro-L-arginine methyl ester ENDOTHELIUM-DERIVED relaxing factor (EDRF) has been identified as NO or a closely related molecule synthesized from the guanidino group of L-arginine (16). The continuous release of NO from endothelium (9) appears to play an important role as an intrinsic modulator of blood flow in various tissues. It is becoming apparent that NO also may impact on the interactions between inflammatory cells and vascular endothelium. NO has been shown to block platelet aggregation and to reduce platelet adhesion to endothelial cell monolayers (17, 18) . We recently demonstrated that NO inhibits leukocyte-endothelial cell adhesive interactions in postcapillary venules. This conclusion was based on the fact that analogues of L-arginine, including NG-monomethyl L-arginine (L-NMMA) and NG-nitro-L-arginine methyl ester (L-NAME), which inhibit NO production (19), also promote the adherence and emigration of leukocytes in postcapillary venules (13). Characteristic features of the inflammatory response include an increase in vascular fluid and protein leakage as well as leukocyte activation and adhesion in postcapillary venules. Activated granulocytes produce superoxide, which is known to inactivate rapidly the NO produced by vascular endothelium (8, 20) . Thus it is conceivable that the inactivation of NO by superoxide may be a key step in the leukocyte-dependent microvascular dysfunction that is observed at the onset of inflammation. With this in mind, and in view of the fact that inhibition of NO production promotes leukocyte adhesion, the objectives of this study were to determine 1) whether inhibition of NO synthesis compromises the barrier function of the microvasculature and 2) whether the changes in vascular fluid and protein efflux resulting from inhibition of NO synthesis are dependent on leukocyte-endothelial cell adhesion.
METHODS

Surgical procedure. Experiments
were performed on 20 cats initially anesthetized with ketamine HCl (75 mg im). The left jugular vein was cannulated, and anesthesia was maintained with the use of pentobarbital sodium. A tracheotomy was performed to maintain a patent airway, and each animal was ventilated artificially. The experimental procedure has been described previously in detail (6, 14) . Briefly, a 45-to 75-g segment of small intestine was isolated from the ligament of Treitz to the ileocecal valve; blood and lymph vessels were maintained intact. The remainder of the small and large intestine was extirpated. The ileal segment and mesenteric pedicle were moistened with saline-soaked gauze and covered with a clear plastic sheet to minimize evaporation and tissue dehydration. The preparation was maintained at 38°C with the use of an infrared heat lamp.
A large lymphatic vessel emerging from the mesenteric pedicle was cannulated, and lymph flow was determined by observing the movement of lymph in a calibrated pipette (0.05-1.0 ml, full scale). Lymph and plasma total protein concentrations (CL and Cp, respectively) were measured with a refractometer (American Optical, Buffalo, NY). The animals were given heparin (10,000 U) intravenously, and an arterial circuit was established between the superior mesenteric (SM) and left femoral arteries. The SM arterial pressure was measured via a Ttube interposed within the arterial circuit by using a Statham P23A transducer.
A large cannula was inserted into the SM vein, and venous outflow was drained into a reservoir mounted on a vertically positioned pulley system. Blood from the reser- voir was returned to the animal via a cannula inserted into the femoral vein. Venous outflow pressure of the intestinal segment was set by adjusting the height of the reservoir and was monitored from a T-connector in the venous circuit. Capillary pressure was measured by using the venous occlusion technique as previously described (5). Systemic arterial pressure was monitored via a cannula inserted into the left carotid artery. All pressure cannulas were positioned at the level of the heart. Blood pressures and intestinal blood flow were recorded continuously by using a Grass physiological recorder (Grass Instruments, Quincy, MA). Heparinized blood from a donor animal was used to prime all the extracorporeal blood circuits. At the end of each experiment the intestinal segment was weighed, and intestinal blood flow, lymph flow, and protein clearance were normalized to 100 g of tissue.
Hemodynamic and vascular protein leakage studies. In the first set of experiments, control values for intestinal blood flow, lymph flow, lymph and plasma protein concentrations, and SM artery, SM vein, and capillary pressures were obtained. The NO synthesis inhibitor L-NAME (Sigma, St. Louis, MO) then was infused at 0.025 prnol. ml-'. min-' for 120 min. Increasing the infusion rate did not cause a further increase in arterial blood pressure. The aforementioned hemodynamic parameters were recorded at 15min intervals. At 60 min of L-NAME infusion, Na nitroprusside was infused at 0.025 prnol. ml-l l min for the final 60 min of the experiment. In some experiments, either the enantiomer p-nitro-D-arginine methyl ester (D-NAME) (0.025 prnol ml-l l min-l) or L-NAME + L-arginine (0.125 pmol l ml-l . min) were infused, and intestinal blood flow, lymph flow, lymph and plasma protein concentrations, and the different blood pressures were monitored for 1 h. In the latter experiments, L-arginine infusion was initiated 30 min before L-NAME infusion. A dose of L-arginine five times higher than that of L-NAME was used, since this was previously reported by both our laboratory (13) and others (9) to be necessary to reverse the L-NAME effects. SM arterial (R,) and venous resistances (R,) were calculated as R, = (PSMA -PC&/ QSMA and Rv = (PCAP -PVEN)/QSMA where PsMA is SM arterial pressure, P SMv is SM venous pressure, PCAp is capillary pressure, and Qs MA is SM arterial blood flow. Vascular permeability studies. In a second group of studies, the osmotic reflection coefficient (gd) was determined as previously described (7). Initially, control values for intestinal lymph flow and CL and Cp were obtained at a local venous pressure of 5 mmHg. Venous pressure was then elevated in lommHg increments up to 40 mmHg, allowing for a steady state at each pressure. Once steady-state values were obtained at 40 mmHg for intestinal lymph flow, CL, and Cp, L-NAME was infused for 60 min (0.025 pmol . ml-l. min-l), and lymph flow, and CJC, were obtained again at 15-min intervals. At 30 min of L-NAME infusion, Na nitroprusside was infused at 0.025 pm01 l ml-l l min-l for the final 30 min of the experiment. The cd was estimated by using the steady-state relationship between the lymph-to-plasma protein concentration ratio (CJC,) and lymph flow before and after L-NAME infusion (7).
Leukocyte-dependent vascular protein leakage. In another set of experiments, the contribution of polymorphonuclear leukocytes to the L-NAME-induced vascular protein leakage was examined. Animals were pretreated with a monoclonal antibody directed against the common ,&subunit (CD18) of the leukocyte adhesion glycoprotein complex CDlI/CDlS (MoAb IB4, 1 mg/ kg iv) (10-12). This dose of MoAb IB4 abolishes L-NAMEinduced leukocyte adherence in feline mesenteric venules (13). Control values for intestinal blood flow, lymph flow, CL and Cp, and SM arterial pressure were obtained, and then L-NAME (0.025 prnol. ml-l l min-') was infused for 1 h during which all parameters were measured at 15-min intervals.
Intravital microscopy experiments.
The cat mesentery was prepared for in vivo microscopic observation as described previously (3). Single unbranched mesenteric venules (diam 25-35 pm; length 250 pm) were observed through an intravital microscope (Leitz, Ortholux II), and a video camera (Dage, MTI) mounted on the microscope projected the image onto a color video monitor. The images were recorded by using a videocassette recorder for playback analysis of leukocyte adhesion and emigration. A leukocyte was defined as adherent to venular endothelium if it remained stationary for 30 s or more. Only one venule was observed and analyzed per cat. After all hemodynamic parameters were in a steady state, the mesenteric venule was recorded for 5 min, and L-NAME (0.025 prnol.
ml-l l rein-l) then was infused into the SM artery for 90 min. A video recording (5 min) was obtained at 60 min, then Na nitroprusside was infused in combination with L-NAME for the last 30 min, and a final 5-min recording was acquired. Statistical analyses. Conventional statistical methods, an analysis of variance, and the Scheffe post hoc test were used. All values are expressed as means t SE, and statistical significance was set at P < 0.05. Table 1 summarizes the steady-state (60-min values) hemodynamic alterations observed during local intraarterial infusion of L-NAME; a 44% increase in SM arterial pressure and a 25% reduction in intestinal blood flow were observed within the first 30 min and lasted for the duration of the L-NAME infusion. Higher concentrations of L-NAME did not alter these parameters further, and infusion of D-NAME had no effect on any parameter measured in this study (data not shown). The effects of L-NAME were abolished with Na nitroprusside, which returned both parameters toward control levels. Table 1 also summarizes the changes in precapillary and post- capillary resistances as well as capillary pressure during infusions of L-NAME with or without Na nitroprusside. Precapillary resistance increased almost 100% during the L-NAME infusion period, whereas the postcapillary resistance response was less pronounced, i.e., a 40% increase in venous resistance was observed at 60 min of L-NAME infusion. Capillary hydrostatic pressure during L-NAME infusion was not statistically different from control, although there was a tendency for capillary pressure to fall. Na nitroprusside attenuated the increase in precapillary and postcapillary resistances and significantly decreased capillary hydrostatic pressure. Figure 1 demonstrates the changes in vascular fluid and protein leakage induced by L-NAME in the presence or absence of Na nitroprusside.
RESULTS
Lymph flow increased fivefold after 15 min of L-NAME infusion and remained L-NAME (0.025 pmole/ml/min) at this level for the remainder of the infusion period. An increase in lymph flow of this magnitude might be expected to dilute the amount of protein within the interstitium and thereby decrease C&p. In fact, C&p remained unchanged, so the vascular protein clearance (CJC, x lymph flow) and the lymph protein flux (CL x lymph flow) increased proportionately to intestinal lymph flow. Administration of nitroprusside at 60 min of L-NAME infusion reversed the L-NAME-induced vascular protein and fluid leakage. Pretreatment of animals with L-arginine prevented the L-NAME-induced increase in microvascular protein and fluid flux as well as vascular protein clearance (Table 2 ). D-NAME had no effect on vascular fluid and protein leakage.
To determine whether the increase in vascular protein leakage was a result of capillary recruitment or increased vascular permeability, the capillary reflection coefficient was measured (Fig. 2) . Under control conditions, intestinal vascular permeability
(1 -a) ranged from 0.15 to 0.22. Vascular permeability approximately doubled during the initial 30 min of L-NAME infusion. When nitroprusside was coadministered, vascular permeability was restored to control values. Figure 3 illustrates the L-NAME-induced vascular pro- -100 g-l ml -mine1 ml -mine1 * 100 g-l * 100 g-' during infusion of either L-NAME or L-NAME plus Na nitroprusside.
*P < 0.05 relative to control; tP < 0.05 relative to 30 min of L-NAME. tein leakage observed in the presence of MoAb IB*, which is known to prevent L-NAME-induced leukocyte adhesion completely (13). The early (first 15 min) increase in vascular protein leakage was unaffected by MoAb IB,; at least fou .rfold increases i n vascular fluid and protein flux were observed. MoAb IB4 pretreatment induced a significant reduction in microvascular protein and fluid leakage after the first 15 min, and by 1 h of L-NAME infusion less than a twofold increase in fluid and protein leakage could be detected relative to the control group. It should be noted that, in the untreated group, vascular protein and fluid leakage remained elevated for the entire infusion period. Infusion of D-NAME (30 min) alone did not significantly alter intestinal lymph flow (94 t 16% of control), vascular protein clearance (97 t l3%), or lymph protein flux (98 t 12%).
L-NAME infusion into the SM artery produced a substantial increase in leukocyte adhesion (2.7 t 1.8 to 27.7 t 11.3 1 eu k ocv es t per lOO-urn-long venule). The onset of leukocyte adhesion occurred between 15 and 25 min and reached a peak between 30 and 45 min. Na nitroprusside administration reduced the number of adherent leukocytes by 59.5 t 13.5% within 30 min. It should be noted that Na nitroprusside dramatically reduced the blood velocity and shear forces within the venules, so the remainder of the adherent leukocytes may have been stationary rather than firmly attached to the endothelium.
DISCUSSION
The results of this study suggest that inhibition of NO synthesis with the L-arginine analogue L-NAME causes a rapid increase in vascular fluid filtration and vascular protein clearance and an increase in microvascular permeability. D-NAME, the biologically inactive enantiomer, did not affect microvascular function, whereas Larginine almost entirely prevented the increase in vascular protein and fluid leakage induced by L-NAME. These data indicate that inhibition of endogenous release of NO from endothelial cells, mast cells, smooth muscle, macrophages, or neutrophils leads to increased microvascular permeability to plasma proteins. This hypothesis is supported further by the observation that nitroprusside, a nitrogen oxide-containing compound that releases NO when it interacts with plasma, completely reversed the increase in vascular fluid and protein efflux and the rise in microvascular permeability. Although nitroprusside may have some nonspecific effects, these data are consistent with the view that continuous release of NO plays an important role in minimizing the loss of fluid and protein out of the vasculature.
Inhibition of NO has been reported previously to increase leukocyte adhesion to postcapillary venules (13). One objective of this study was to test whether inhibition of NO formation by L-NAME would produce a leukocytedependent increase in fluid and protein flux out of the vasculature. To achieve this objective, some animals were pretreated with a monoclonal antibody (MoAb IB,) directed against the common ,&subunit (CD18) of the leukocyte adhesion glycoprotein complex CDll/CD18 (23). We have reported previously that MoAb IB4 entirely prevents L-NAME-induced leukocyte adherence and emigration in mesenteric venules (13). Pretreatment with MoAb IB4 in this study produced a significant timedependent reduction in the vascular protein leakage induced by L-NAME. This observation suggests that adherent leukocytes are responsible for a significant portion of the L-NAME-induced increase in fluid and protein leakage. Furthermore, the data suggest that continuous release of NO plays an important role in maintaining an intact endothelial cell barrier largely because NO acts to inhibit leukocyte adherence. Although the exact mechanism by which leukocytes mediate the microvascular dysfunction induced by inhibition of NO production remains unclear, neutrophil-derived oxidants and proteases have been implicated in the microvascular dysfunction associated with a number of inflammatory models (2, 21, 24) .
A surprising finding in this study was the observation that the initial (first 15 min) increase in fluid and protein leakage could not be inhibited by MoAb IB4, suggesting that an early, leukocyte-independent process also contributes to the microvascular dysfunction elicited by inhibition of NO synthesis. Additional support for a leukocyte-independent mechanism is the observation that leukocyte adherence begins at -15-25 min and reaches a peak at 30-45 min of L-NAME infusion. Although the mechanism underlying the early onset of microvascular fluid and protein leakage is presently unknown, several possibilities warrant attention.
A substantial increase in microvascular pressure could account for the increased fluid and protein flux caused by L-NAME. However, we observed that capillary hydrostatic pressure actually dropped slightly (Fig. 1) when NO production was inhibited with L-NAME. A second possibility is that L-NAME infusion leads to the recruitment of capillaries, which in turn would increase the surface area for fluid and protein filtration out of the microvasculature. However, this possibility also appears untenable inasmuch as 1) our measurement of microvascular permeability
(1 -0 in Fig. 3) is not influenced by alterations in capillary surface area provided filtration rate independence is achieved (7), and 2) vasoconstrictors such as L-NAME generally cause derecruitment of mesenteric capillaries (4). Another possibility is that inhibition of NO may lead to activation of other inflammatory cells, including platelets, mast cells, or macrophages, which in turn release substances that can increase microvascular permeability. Inhibition of NO synthesis promotes platelet adhesion, an event that is known to cause endothelial cell injury (15, 22) . A final possibility is that the continuous production of NO may serve to scavenge small fluxes of superoxide produced by endothelial cells. Inhibition of NO production would allow for an accumulation of superoxide and/or hydrogen peroxide, which are known to alter microvascular integrity (1). The latter two possibilities are tenable explanations for the early rise in vascular protein efflux induced by L-NAME, and both mechanisms warrant further investigation.
